• S1 Episode 2: Biomarkers and Targeted Therapies for Lung Cancer

  • 2022/08/11
  • 再生時間: 24 分
  • ポッドキャスト

S1 Episode 2: Biomarkers and Targeted Therapies for Lung Cancer

  • サマリー

  • Drs Jacob Sands and Pasi Jänne discuss the effectiveness of biomarkers and targeted therapies for lung cancer.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969533). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US health care professionals.

    Resources

    Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma https://www.nejm.org/doi/full/10.1056/nejmoa0810699

    The Value of Next-Generation Sequencing in Patients With Non-Small Cell Lung Cancer https://www.medscape.org/viewarticle/975903

    ctDNA Shows Promise for Assessing Lung Cancer Treatment Response https://www.medscape.com/viewarticle/965587

    Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer https://www.nejm.org/doi/10.1056/NEJMoa2005653

    Structure-Based Classification Predicts Drug Response in EGFR-Mutant NSCLC https://www.nature.com/articles/s41586-021-03898-1

    Targeting Uncommon EGFR Mutations in Advanced NSCLC https://reference.medscape.com/recap/952720

    Afatinib Prescribing Information https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Gilotrif/Gilotrif.pdf?DMW_FORMAT=pdf

    Amivantamab Prescribing Information https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf

    Mobocertinib Prescribing Information https://content.takeda.com/?contenttype=pi&product=exkivity&language=eng&country=usa&documentnumber=1

    Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer https://www.nejm.org/doi/10.1056/NEJMoa1713137

    Real-World Incidence and Impact of Pneumonitis in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors: a Multi-institutional Cohort Study https://jitc.bmj.com/content/10/6/e004670.long

    続きを読む 一部表示

あらすじ・解説

Drs Jacob Sands and Pasi Jänne discuss the effectiveness of biomarkers and targeted therapies for lung cancer.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969533). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US health care professionals.

Resources

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma https://www.nejm.org/doi/full/10.1056/nejmoa0810699

The Value of Next-Generation Sequencing in Patients With Non-Small Cell Lung Cancer https://www.medscape.org/viewarticle/975903

ctDNA Shows Promise for Assessing Lung Cancer Treatment Response https://www.medscape.com/viewarticle/965587

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer https://www.nejm.org/doi/10.1056/NEJMoa2005653

Structure-Based Classification Predicts Drug Response in EGFR-Mutant NSCLC https://www.nature.com/articles/s41586-021-03898-1

Targeting Uncommon EGFR Mutations in Advanced NSCLC https://reference.medscape.com/recap/952720

Afatinib Prescribing Information https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Gilotrif/Gilotrif.pdf?DMW_FORMAT=pdf

Amivantamab Prescribing Information https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf

Mobocertinib Prescribing Information https://content.takeda.com/?contenttype=pi&product=exkivity&language=eng&country=usa&documentnumber=1

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer https://www.nejm.org/doi/10.1056/NEJMoa1713137

Real-World Incidence and Impact of Pneumonitis in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors: a Multi-institutional Cohort Study https://jitc.bmj.com/content/10/6/e004670.long

S1 Episode 2: Biomarkers and Targeted Therapies for Lung Cancerに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。